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Abstract
Background: Tumor-associated macrophages (TAMs) promote tumor progression and have an effect on survival in
human cancer. However, little is known regarding their influence on tumor progression and prognosis in human
hilar cholangiocarcinoma.
Methods: We analyzed surgically resected tumor specimens of hilar cholangiocarcinoma (n = 47) for distribution and
localization of TAMs, as defined by expression of CD68. Abundance of TAMs was correlated with clinicopathologic
characteristics, tumor recurrence and patients’ survival. Statistical analysis was performed using SPSS software.
Results: Patients with high density of TAMs in tumor invasive front (TIF) showed significantly higher local and overall
tumor recurrence (both ρ < 0.05). Furthermore, high density of TAMs was associated with decreased overall (one-year
83.6 % vs. 75.1 %; three-year 61.3 % vs. 42.4 %; both ρ < 0.05) and recurrence-free survival (one-year 93.9 % vs. 57.4 %;
three-year 59.8 % vs. 26.2 %; both ρ < 0.05). TAMs in TIF and tumor recurrence, were confirmed as the only
independent prognostic variables in the multivariate survival analysis (all ρ < 0.05).
Conclusions: Overall survival and recurrence free survival of patients with hilar cholangiocarcinoma significantly
improved in patients with low levels of TAMs in the area of TIF, when compared to those with a high density of
TAMs. These observations suggest their utilization as valuable prognostic markers in routine histopathologic
evaluation, and might indicate future therapeutic approaches by targeting TAMs.
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Background
Hilar cholangiocarcinoma represents the most common
cancer arising within the extrahepatic bilary tree and ex-
tended liver resection or liver transplantation following a
highly selective protocol with combined neoadjuvant ra-
diochemotherapy represent the only curative treatment
[1]. High risk of tumor recurrence remains a serious
problem, even if liver resection is combined with extra-
hepatic hilar en bloc resection [2, 3]. The seventh edition
of the TNM classification separates extrahepatic bile duct
tumors into perihilar and distal tumors [4]. Modifications
of staging systems for hilar cholangiocarcinoma in order
to enhance prognostic accuracy have recently been pro-
posed [5, 6]. There is an urgent need to identify prognostic
markers associated with recurrence and survival. A better
understanding of underlying biological mechanisms might
further help to improve treatment options in this tumor
entity.
All classes of leukocytes are found within malignant
tumors. Tumor-associated macrophages (TAMs) constitute
up to 50 % of this leukocyte cell population. Monocytes are
recruited from the circulation at sites of injury, inflamma-
tion, infection, and malignancy, where they differentiate
into tissue macrophages [7–10]. TAMs are diffusely found
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throughout tumorous tissue in localized zones, e.g. tumor
invasive fronts (TIF), around ductal and in tumor stromal
areas [11, 12]. Experimental data have highlighted a
fundamental role of TAMs in tumor progression [13].
High abundance of TAMs is associated with an unfavorable
prognosis in hepatocellular carcinoma (HCC), esophageal,
ovarian and breast cancer and recent studies have empha-
sized a link between their abundance in tumor tissues and
the process of tumor spread [14–19].
The clinical significance of infiltrating TAMs remains
uncertain in hilar cholangiocarcinoma. The aim of this
study was therefore to evaluate the relationship between
abundance of TAMs and a presumed association with
tumor growth, metastasis, recurrence and clinical prog-
nosis in hilar cholangiocarcinoma.
Methods
Patients and tumor samples
A total of 47 patients who underwent major hepatectomy
between January 1996 and December 2002 for hilar
cholangiocarcinoma were included in the study. Hilar
cholangiocarcinoma was confirmed histopathologically
and classified according to the American Joint Committee
on Cancer/Union Internationale Contra Cancrum tumor-
node-metastasis classification (UICC) classification. Writ-
ten informed consent was obtained from all patients. This
study was approved by the ethics committee of Charité –
Universitätsmedizin Berlin.
In all patients liver resection was in curative intent.
None of the patients received neoadjuvant radio- and/or
chemotherapy prior to surgery. None of the patients died
in the postoperative course. In 37 of 47 (78.7 %) patients a
curative resection was accomplished (histopathologically
confirmed negative resection margin; R0 status), in 5
patients (10.6 %) R1 status was diagnosed and in another
5 (10.6 %) patients R2 situation was pathologically
confirmed.
Formalin-fixed, paraffin-embedded tumor samples were
retrieved from the files of the Institute of Pathology.
Tissue blocks embedding a representative sample of
the tumor were used. Histological diagnosis of the pri-
mary tumor stage and nodal status were determined by
hematoxylin and eosin (H&E) stained sections. The
clinicopathological characteristics of the study popula-
tion are depicted in Table 1.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tumor sections
(5 μm thick) were dewaxed and rehydrated. Antigen re-
trieval was performed by heating the slides in 10 mM
Tris buffer with 1 mM EDTA (pH 9) in a streamer for
20 min. Endogenous peroxidase activity was inhibited
with 3 % H2O2 for 5 min. After washing with Tris buff-
ered saline (TBS) with tween, the endogenous biotin was
suppressed by sequential incubations with 0,1 % avidin
and 0,01 % biotin (Dako, Glostrup, Denmark) for 10 min
each at room temperature. Additional nonspecific bind-
ing sites were blocked with 3 % skimmed milk powder
for 30 min at room temperature. Tissue sections were
Table 1 Clinicopathological characteristics of the patients
included in the study
Clinicopathological characteristics
Variable Value (%)
No. of patients 47
Gender
Male 23 (48.9 %)
Female 24 (51.1 %)
Patient age
≤60 23 (48.9 %)
>60 24 (51.1 %)
Histologic differentiation
Well/Moderate 40 (85.1 %)
Poor 7 (14.9 %)
Pathologic T stage
T2 16 (34.0 %)
T3 31 (66.0 %)
Pathologic N stage
Negative 32 (69.1 %)
Positive 15 (31.9 %)
Perineural sheath infiltration
Negative 4 (8.5 %)
Positive 43 (91.5 %)
Lymphangiosis carcinomatosa
Negative 25 (53.2 %)
Positive 22 (46.8 %)
Perivascular lymphangiosis
Negative 24 (51.1 %)
Positive 23 (48.9 %)
Vascular invasion
Negative 32 (68.1 %)
Positive 15 (31.9 %)
Tumor recurrence
Without 22 (46.8 %)
With 25 (53.2 %)
Local recurrence
Without 27 (57.4 %)
With 20 (42.6 %)
Distant metastases
Without 36 (76.6 %)
With 11 (23.4 %)
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incubated with the monoclonal mouse antibody anti-
human CD68 Clone PG-M1 (1:50, Dako, Glostrup,
Denmark) for 30 min at room temperature. The universal
LSAB+ system-HRP (Dako, Glostrup, Denmark) and the
DAB+ liquid substrate chromogen system (Dako, Glostrup,
Denmark) was applied for the visualization of the antibody
reaction. The biotinylated anti-rabbit, anti-mouse and anti-
goat immunoglobulin and the streptavidin conjugated
horseradish peroxidase of the universal LSAB+ system was
incubated consecutively for 20 min each. Sections were
counterstained with hematoxylin. Specificity controls were
performed without primary antibody.
Quantification of CD68 density
All specimens were evaluated by three independent re-
searchers (GA, CD and IP), and an independent pathologists
(KS), without any knowledge of prognosis or clinicopatho-
logical variables. TAMs were defined by their expres-
sion of CD68. For quantification of infiltrating TAMs
the whole tumor area was thoroughly investigated for
presence of CD68-positive cells. The evaluation of TAMs
density was performed as percent immunohistochemical
CD68 staining related to tumor cell amount.
The density of TAMs in the whole tumor area (tumor-
ous tissue, TT) was semi-quantitatively classified into the
following categories: 0, negative; 1, 1–25 %; 2, 26–75 %;
and 3, >75 %. For statistical analysis, TT scores 0 and 1
were categorized as low density, and TT scores 2 and 3 as
high density of TAMs. The density of TAMs in the tumor
infiltrating front (TIF) were semi-quantitatively classified
into the following major categories: 0, negative; 1, 1–25 %
and 2, >25 %. For statistical analysis, TIF scores 0 and 1
were categorized as low density or negative, TIF score 2 as
high density (or positive).
Patients with hilar cholangiocarcinoma were divided
into several groups either by ‘low’ or ‘high’ density of
macrophages in tumorous tissue (‘low TT CD68 group’;
n = 24) and ‘high TT CD68 group’; n = 23, respectively),
or ‘low’ or ‘high’ density of TAMs in TIF (‘low TIF CD68
group’ n = 21; and ‘high TIF CD68 group’, n = 26,
respectively).
Statistical analysis
Survival analysis, univariate analysis and Kaplan-Meier
curves were generated with assistance of the SPSS soft-
ware program (Version 19.0.0 / Year 2010). Comparison
of categorical and continuous variables was performed
using the Chi2-test and the Wilcoxon-test, respectively.
Survival data were compared with the log rank-test.
Variables with a significant influence on survival in the
univariate analysis were entered into a cox regression
analysis. A difference was considered significant for p < 0.05.
Results
The median follow-up after resection in all patients was
28 months (range 2.3 to 105.7 months). The overall 1-,
3- and 5-year survival of our cohort was 78.8, 51.4 and
31.7 %, respectively (Fig. 1a). The overall 1-, 3- and 5-
year recurrence-free survival rates were 68.8, 40.1 and
31.3 %, respectively (Fig. 1e). 27 (57.4 %) of 47 patients
died within the follow-up interval. 25 patients (53.2 %)
developed tumor recurrence and 24 (51.0 %) patients
died for recurrence of hilar cholangiocarcinoma. Local
tumor recurrence was seen in 20 (42.6 %) patients, while
5 (10.6 %) patients developed distant metastases without
manifestation of local recurrence (Table 1). In 6 (12.7 %)
patients with local recurrence of hilar cholangiocarci-
noma a metastatic spread of the tumor to distant sites
was detected. 3 (6.3 %) patients died without evidence for
tumor-related cause and had no signs of tumor recurrence
at the time of death.
Macrophage distribution in hilar cholangiocarcinoma
TAMs showed a vast homogenous distribution in tumor
stroma and tumor parenchyma, TIF and perivascular areas,
respectively (Fig. 2a-c). No clusters or ‘clumping’ of TAMs
in tumor tissue has been observed. The infiltration patterns
did not reveal any preference for the tumor perivascular
areas. The majority of TAMs were apparently located in
direct contact with or adjacent to tumor cells. Interestingly,
a high density of TAMs was observed at TIF in 26 pa-
tients (TIF score 2/high density/positive), while rest of
tumor specimens (n = 21) displayed only a scarce or
complete absence of infiltrating TAMs (TIF scores 0
and 1/low density/negative) (Fig. 2c).
The presence of tumor-infiltrating CD68-positive
macrophages in tumor invasive front associates with
tumor recurrence in patients with hilar cholangiocarcinoma
High abundance of macrophages in TIF correlated with a
significantly increased overall tumor recurrence. 18 (69.2 %)
of 26 patients in high TIF CD68 group displayed tumor re-
currence (ρ = 0.015). In the low TIF CD68 group 7 (33.3 %)
of 21 patients had recurrent disease. Moreover, patients with
high levels of macrophages in TIF showed a significantly en-
hanced incidence of local tumor recurrence (ρ = 0.0001).
17 (65.4 %) of 26 patients in the high TIF CD68 group
suffered a local tumor recurrence, whereas 3 (14.3 %)
out of 21 patients in the low TIF CD68 group did not
show local tumor recurrence (Table 2). After R0 resection
(n = 37), a low CD68 abundance in TIF (‘R0 low CD68
TIF group’; n = 16) correlated with a significantly lower
rate of disease recurrence, as well. 11 (68.8 %) and 15
(93.8 %) patients in the low CD68 TIF group did not
develop overall or local tumor recurrence following R0
surgery (ρ = 0.064 and ρ = 0.001, respectively).
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Fig. 1 (See legend on next page.)
Atanasov et al. BMC Cancer  (2015) 15:790 Page 4 of 9
Other well established common prognostic factors
were assessed, as well. 5 (19.2 %) of 26 patients in
high TIF CD68 group had poor histologic tumor dif-
ferentiation. In the low TIF CD68 group 2 (9.5 %) of
21 patients displayed poor histologic differentiation
(ρ = 0.307). Related to angioinvasion, 8 (30.8 %) of 26
and 7 (33.3 %) of 21 patients in the high or low CD68
TIF group, respectively, showed a microscopic angioinva-
sion (ρ = 0.549). 18 (69.2 %) of 26 and 13 (61.9 %) of 21
patients in the high or low CD68 TIF group, respectively,
showed a more advanced T stage (ρ = 0.413). Related to
perineural sheet infiltration, 3 (11.5 %) of 26 and 1 (4.8 %)
of 21 patients in the high or low CD68 TIF group, respect-
ively, showed an absence of perineural sheet infiltration
(ρ = 0.390).
Prognostic significance of CD68-positive macrophages in
hilar cholangiocarcinoma
Next, we analyzed whether TAMs in addition to other
clinicopathological parameters predict survival after resec-
tion for hilar cholangiocarcinoma. In the univariate analysis
R category, overall and local tumor recurrence, and low
density of macrophages in TIF were associated with a sta-
tistically significant improvement of patient survival after
resection (ρ = 0.039, ρ = 0.001, ρ = 0.001 and ρ = 0.036, re-
spectively). As related to recurrence-free survival, in univar-
iate analysis only low macrophages in TIF (ρ = 0.013) were
associated with a statistically significant improvement.
In multivariate analysis presence of TAMs in TIF (re-
lated to recurrence-free survival for all patients, as well
for R0 status only) and tumor recurrence were
(See figure on previous page.)
Fig. 1 a Overall survival after surgery for hilar cholangiocarcinoma (n = 47). b Overall survival after surgery for hilar cholangiocarcinoma (n = 37)
according to R status. c Overall survival after surgery referred to CD68-positve TAMs in the tumor infiltration front (TIF) regardless of R status (n = 47).
d Overall survival after surgery referred to TAMs in the tumor infiltration front (TIF) after R0 resection (n = 37). e Recurrence-free survival of all patients
after surgery for hilar cholangiocarcinoma (n = 47). f Recurrence-free survival after surgery correlated to TAMs in the tumor invasive front (TIF) regardless
of R status (n = 47). g Recurrence-free survival correlated to TAMs in the tumor invasive front (TIF) following R0 surgery (n = 37)
Fig. 2 a CD68-positive macrophages in normal liver tissue. Normal liver parenchyma revealed a homogenous infiltration pattern with no preference
for perivascular areas or clumping of TAMs. Original magnification: x 200; scale bar = 50 μm. b Hilar cholangiocarcinoma stained with mAb
CD68 PG-M1 with a high abundance of TAMs (tumorous tissue “TT” score 3). Original magnification: x 200; scale bar = 50 μm. c Tumor infiltration front
(TIF) positive for CD68-positive TAMs (TIF score 2 / high abundance / positive). Original magnification: x 200; scale bar = 50 μm
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identified as independent prognostic factors for survival
(all ρ < 0.05; Table 3). Other well established common
prognostic factors, e. g. T stage and angioinvasion, did
not exert prognostic significance in the current work.
Influence of macrophages on overall and recurrence-free
survival in hilar cholangiocarcinoma
Based on the identification of TAMs in TIF as an inde-
pendent prognostic factor in both the univariate and
multivariate analysis, we investigated its effect on patients’
survival in hilar cholangiocarcinoma. The presence of
TAMs in TIF affected patients’ survival after resection for
hilar cholangiocarcinoma. Univariate analysis revealed a
significantly better survival in the low TIF CD68 group
(ρ = 0.013). The overall survival rates were 83.6 and
61.3 % at 1- and 3-year post surgery in comparison with
75.1 and 42.4 % at 1- and 3-year following resection for
patients with low and high abundance of CD68-positive
macrophages in TIF, respectively (Fig. 1c). Moreover, a
low density of CD68-positive cells in TIF correlated
with a significantly improved recurrence free survival.
The 1-, 3-, and 5-year recurrence-free survival rates of
patients with tumors that displayed low density of
CD68-positive cells in TIF were 93.9, 59.8 and 51.8 %,
whereas the 1-, 3-, and 5-year recurrence-free survival
rates of patients with tumors with a high abundance of
CD68-positive cells in TIF were 57.4, 26.2 and 12.1 %,
respectively (Fig. 1f). The difference was statistically sig-
nificant (p = 0.009). Following R0 resection, a low abun-
dance of CD68-positive cells in TIF correlated with an
improved overall and recurrence-free survival, as well
(p = 0.19 and p = 0.023, respectively) (Fig. 1b, d, g).
Histologic differentiation and perineural sheet infiltra-
tion showed a distinct trend towards an improved over-
all survival, though without reaching statistical significance
(ρ = 0.103 and ρ = 0.224, respectively). Overall survival and
recurrence free survival of patients with hilar cholangiocar-
cinoma were significantly better in patients with low levels
of TAMs in the area of TIF when compared to those with
a high density of TAMs.
Discussion
Analyzing immunoreactivity for CD68-positive TAMs in
tumor samples from patients who underwent resection
for hilar cholangiocarcinoma, we were able to show that
(1.) a high abundance of CD68 in TIF is a risk factor for
local recurrence and overall tumor recurrence, (2.) serves
as an independent prognostic factor for survival, and (3.)
translates into dismal overall as well as recurrence-free
survival rates.
High density of TAMs in TIF was an independent
negative prognostic factor for recurrence-free survival.
Espinosa et al. demonstrated TAMs to correlate with in-
creased microvessel proliferation and enhanced tumor
angiogenesis [20]. Thus, reduced density of CD68 in TIF
might mitigate tumor angiogenesis and improve survival
in hilar cholangiocarcinoma. In the univariate analysis a
negative-margin (R0) tumor resection correlated signifi-
cantly with improved survival; however, this could not
Table 2 Correlation of CD68-positiveTAMs in the tumor invasive
front with clinicopathological characteristics of hilar
cholangiocarcinoma
Clinicopathological analysis
Variable high CD68 low CD68 p
No. of patients 26 21
Gender 0.552
Male 13 (50 %) 10 (47.6 %)
Female 13 (50 %) 11 (52.4 %)
Patient age, years 0.448
≤60 14 (53.8 %) 12 (47.6 %)
>60 12 (46.2 %) 11 (52.4 %)
Histological differentiation 0.307
Well/moderate 21 (80.8 %) 19 (90.5 %)
Poor 5 (19.2 %) 2 (9.5 %)
Pathological T stage 0.413
T2 8 (30.8 %) 8 (38.1 %)
T3 18 (67.9 %) 13 (61.9 %)
Pathological N stage 0.307
Negative 19 (73.1 %) 13 (61.9 %)
Positive 7 (26.9 %) 8 (38.1 %)
Perineural sheath infiltration 0.390
Negative 3 (11.5 %) 1 (4.8 %)
Positive 23 (88.5 %) 20 (95.2 %)
Lymphangiosis carcinomatosa 0.576
Negative 12 (46.2 %) 10 (47.6 %)
Positive 14 (53.8 %) 11 (52.4 %)
Perivascular lymphangiosis 0.552
Negative 13 (50 %) 11 (52.4 %)
Positive 13 (50 %) 10 (47.6 %)
Vascular invasion 0.549
Negative 18 (69.2 %) 14 (66.6 %)
Positive 8 (30.8 %) 7 (33.3 %)
Tumor recurrence 0.015
Without 8 (30.8 %) 14 (66.7 %)
With 18 (69.2 %) 7 (33.3 %)
Local recurrence 0.001
Without 9 (34.6 %) 18 (85.7 %)
With 17 (65.4 %) 3 (14.3 %)
Distant metastases 0.390
Without 19 (73.1 %) 17 (81.7 %)
With 7 (26.9 %) 4 (19.0 %)
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be confirmed in the multivariate analysis which is likely
to be due to the small number of patients with positive-
margin (R1, R2). The clinical characteristics and tumor
specimens of the presented work were retrieved from a
high volume center patient cohort with clinicopathologic
features resembling other studies [21, 22]. In the multi-
variate analysis, only tumor recurrence and high abun-
dance of CD68 in TIF irrespective of R-status proved to
be independent prognostic indicators. A high abundance
of CD68 in TIF was correlated not only with a higher
risk of overall tumor recurrence but also with local tumor
recurrence. These variables are well established indicators
for unfavorable patient outcome and poor long term sur-
vival in hilar cholangiocarcinoma. Hereby, the stronger
influence of TAMs in TIF on patient survival and recur-
rence-free survival compared to R classification may be
caused by correlation with multiple unfavorable clinico-
pathologic characteristics in hilar cholangiocarcinoma.
The tumor mass is a multifaceted playground, where dif-
ferent cell types, including cancer cells, fibroblasts, endo-
thelial and immune-competent cells are entangled into a
constant interaction. Paradoxically, in the majority of
Table 3 Univariate and multivariate analysis of prognostic factors in patients with hilar cholangiocarcinoma
Variable Category Odds ratio p Confidence interval
Univariate analysis
Age ≤60/>60 1.588 0.239 0.735–3.430
Gender male/female 1.287 0.517 0.600–2.761
perivascular lymphangiosis negative/positive 0.734 0.430 0.340–1.583
R-Classification negative/positive 2.325 0.039 1.042–5.189
Histologic differentiation well or moderate/poor 2.141 0.103 0.857–5.344
Vascular invasion negative/positive 1.285 0.569 0.542–3.045
pT pT2/pT3 1.242 0.597 0.557–2.768
pN negative/positive 0.535 0.124 0.242–1.186
Perineural sheet infiltration negative/positive 0.289 0.224 0.039–2.137
Lymphangiosis carcinomatosa negative/positive 0.835 0.651 0.381–1.827
CD68 + TAMs high/low 0.977 0.951 0.457–2.088
CD68 + TAMs in TIF high/low 0.322 0.013 0.132–0.784
Overall Tumor Recurrence negative/positive 0.112 0.001 0.033–0.37
Distant Metastasis negative/positive 0.528 0.111 0.240–1.159
Local Tumor Recurrence negative/positive 0.183 0.001 0.076–0.441
Multivariate analysis
R Classification negative/positive 0.830 0.710 0.312–2.212
Overall Tumor Recurrence negative/positive 0.172 0.024 0.037–0.794
Local Tumor Recurrence negative/positive 0.544 0.432 0.119–2.486
CD68-positive TAMs in TIF high/low 0.856 0.780 0.287–2.553
Multivariate analysis (Recurrence free survival)
R0 & R1/2 surgery/n = 47
R Classification negative/positive 1.935 0.149 0.789–4.743
CD68-positive TAMs in TIF high/low 0.324 0.014 0.132–0.796
R0 & R1/2 surgery/n = 47
only R0 surgery/n = 37
Histologic Differentiation well or moderate/poor 2.549 0.109 0.811–8.012
CD68-positive TAMs in TIF high/low 0.286 0.024 0.097–0.846
only R0 surgery/n = 37
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human solid cancers, cells of the innate immune sys-
tem, especially TAMs, were shown to favor tumor pro-
gression by, i.e., fostering metastasis and suppressing
adaptive immunity. Yet, the lack of routine implemen-
tation of the experimental immunologic rationales as
diagnostic or therapeutic concepts on a clinic daily
basis is striking [23, 24]. In the present work we
propose a well described and ubiquitous type of TAMs,
in particular cells expressing CD68, as simple diagnos-
tic tools prognosticating patient outcome in hilar
cholangiocarcinoma.
In the current work TAMS in TIF were associated with
survival and recurrence free survival and were identified
as independent prognosticator. A rational clinical transla-
tion of these results suggests standardized utilization of
TAMs as prognostic markers in the scope of pathological
evaluation of resected specimens from patients suffering
from hilar cholangiocarcinoma. This could be performed
routinely in the scope of microscopical histological tumor
evaluation as well as in standardized and reliable protocols
on paraffin-embedded tumor specimens after staining
with commercially available and commonly used anti-
bodies against the macrophage marker CD68.
Another possibility for clinical utilization is the targeting
of TAMs in tumors. The pro-tumor features of TAMs
render these cell types attractive targets for biological
anti-cancer therapies. To date, tumor progression is
successfully treated by depletion of TAMs in preclinical
animal models. Moreover, the combination of macrophage
depleting agents with sorafenib, a potent inhibitor of
tyrosine protein kinases (e.g. VEGF and platelet-derived
growth factor receptor (PDGRF)), enhances significantly
the efficacy of sorafenib alone in a xenograft model of he-
patocellular carcinoma [25].
High recurrence rates after surgical resection for hilar
cholangiocarcinoma imply an urgent need for reliable
prognostic markers aiding the selection of appropriate
patients who will benefit from radical surgical strategies.
In particular, suitable patients for liver transplantation
need to be cautiously selected, on grounds of a common
donor organ shortage. CD68-positive TAMs and tumor
necrosis may prove as valuable tools regarding patient
selection. Emerging experimental studies reveal a poten-
tial role for selective in vivo visualization of circulating
monocytes/macrophages and TAMs by magnetic reson-
ance imaging (MRI) techniques allowing 3D spatial reso-
lution up to 50 μm [26–31]. With a further development
and clinical implementation of these imaging tools the
evaluation of TAMs could offer an additional diagnostic
modality for the patient selection for further treatment
strategies.
However, drawbacks in the utilization of CD68 as a se-
lection criterion prior surgery are to be considered, as
well. To date, reliable clinical evaluation of these markers
is only possible in resected tumor specimens following
surgery. It should be also considered that tumor biopsies
prior surgery will not provide representative tissue speci-
mens and will not conform to the principles of a surgical
approach using a ‘no-touch technique’ [32].
Conclusions
In conclusion, in the current study we demonstrate for
the first time that presence of CD68-positive TAMs in
tumor invasive front correlates with tumor recurrence and
serves as an independent prognostic factor for survival in
hilar cholangiocarcinoma. Thus, TAMs may be crucially
involved in the progression of this tumor entity and their
utilization as a diagnostic tool or targeting TAMs, may de-
liver new therapeutic approaches in this cancer.
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